AI > Chemistry and pharma
Creating better treatments with AI
The increasing use of AI promises to revolutionise drug discovery, but only if laboratories can organise their data, writes Robert Roe
I
nvestment in artificial intelligence and its use in drug discovery is increasing rapidly as organisations realise the
potential of this growing market. Causaly, an AI platform for drug
discovery and biomedical research, recently raised $60 million. Another AI drug discovery specialist, Recursion, has seen its own valuation surge after a $50 million investment from Nvidia. Recursion has four clinical trials and multiple preclinical projects targeting various cancers and diseases. The company acquired two AI drug discovery companies, Cyclica – a digital chemistry software suite and Valence – an AI/ML- powered chemical property prediction software, for $87 million. In July 2023, Recursion announced a $50 million investment from GPU maker Nvidia through a private investment
18 Scientific Computing World Summer 2023
in public entity (PIPE). Recursion also announced plans to accelerate the development of its AI foundation models for biology and chemistry, which, in collaboration with Nvidia, it intends to optimise and distribute to biotechnology companies using Nvidia cloud services. Chris Gibson, Co-founder and CEO
of Recursion, said: “With our powerful dataset and Nvidia’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.” Developing a new drug is an arduous
process that typically spans more than a decade, involving extensive research, development and rigorous clinical trials. There is real urgency to expedite this process. It would enable
GogOfVector/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42
